Effect of myo-inositol on ovulation induction outcomes in women with polycystic ovary syndrome
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20262078Keywords:
Polycystic ovary syndrome, Myo-inositol, Ovulation induction, InfertilityAbstract
Background: Polycystic ovarian syndrome (PCOS) is a common endocrine condition affecting reproductive-aged women that is distinguished by insulin resistance, hyperandrogenism, and anovulation. Myo-inositol, an insulin-sensitizing drug, has emerged as a promising complementary therapy for enhancing reproductive outcomes. The study aimed to assess whether myo-inositol supplementation affected ovulation induction outcomes in women with PCOS undergoing reproductive treatments.
Methods: This investigation was carried out at Department of Obstetrics and Gynecology, Asgar Ali Medical Hospital, Dhaka, Bangladesh from January 2023 to December 2025. A prospective comparison study included 100 women diagnosed with PCOS based on the Rotterdam criteria. Participants were divided into two groups: the control group (n=50) received standard ovulation induction, and the myo-inositol group (n=50) received 2 grams of myo-inositol twice daily. The primary outcomes were ovulation confirmation and endometrial thickness. The data were entered and analyzed with statistical package for the social sciences (SPSS) version 26.
Results: Baseline characteristics were comparable among groups. The myo-inositol group had significantly greater ovulation rates (74.0% versus 56.0%, p=0.04) and endometrial thickness (8.1±1.4 mm versus 7.4±1.3 mm, p=0.01) than the control group. Mid-luteal progesterone levels were higher in the myo-inositol group (10.6±4.1 ng/ml versus 8.9±3.7 ng/ml, p=0.03). Multivariable analysis revealed that myo-inositol supplementation is an independent predictor of ovulation (adjusted OR 2.30, 95% CI 1.01-5.24, p=0.047).
Conclusion: Myo-inositol supplementation dramatically improves ovulation rates and endometrial growth in women with PCOS who are undergoing ovulation induction, making it an excellent adjuvant therapy for improving reproductive outcomes in this population.
References
Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2(1):1-8.
Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod. 2012;27(1):14-24.
Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602-18.
Ding T, Hardiman PJ, Petersen I, Wang FF, Qu F, Baio G. The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. Oncotarget. 2017;8(56):96351.
Wijeyaratne CN, Dilini Udayangani SA, Balen AH. Ethnic-specific polycystic ovary syndrome: epidemiology, significance and implications. Expert Rev Endocrinol Metab. 2013;8(1):71-9.
Talukder A, Tithi TA, Rumi MH, Muyeed A. Prevalence of polycystic ovary syndrome and its impact on psychological distress: a comparative study among urban and rural reproductive-aged women in Bangladesh. medRxiv. 2025;2025:07.
Hossain MA, Arafat MY, Kundu S. Spatial patterns and determinants of anxiety, depressive symptoms and their co-occurrence among currently married women of reproductive age in Bangladesh. Cambridge Prisms Glob Ment Health. 2026;13:e4.
Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981-1030.
Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119-29.
Unfer V, Facchinetti F, Orrù B, Giordani B, Nestler J. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect. 2017;6(8):647-58.
Genazzani AD, Santagni S, Ricchieri F, Campedelli A, Rattighieri E, Chierchia E, et al. Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome. J Obstet Gynaecol Res. 2014;40(5):1353-60.
Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012;28(7):509-15.
Facchinetti F, Orru B, Grandi G, Unfer V. Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. Gynecol Endocrinol. 2019;35(3):198-206.
Laganà AS, Garzon S, Casarin J, Franchi M, Ghezzi F. Inositol in polycystic ovary syndrome: restoring fertility through a pathophysiology-based approach. Trends Endocrinol Metab. 2018;29(11):768-80.
Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci. 2012;16(5):575-81.
Vitagliano A, Saccone G, Cosmi E, Visentin S, Dessole F, Ambrosini G, et al. Inositol for the prevention of gestational diabetes: a systematic review and meta-analysis of randomized controlled trials. Arch Gynecol Obstet. 2019;299(1):55-68.
Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012;28(7):509-15.
Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci. 2012;16(5):575-81.
Januszewski M, Issat T, Jakimiuk AA, Santor-Zaczynska M, Jakimiuk AJ. Metabolic and hormonal effects of a combined myo-inositol and D-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS). Ginekol Pol. 2019;90(1):7-10.
Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol. 2007;23(12):700-3.
Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007;11(5).
Unfer V, Carlomagno G, Rizzo P, Raffone E, Roseff S. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. Eur Rev Med Pharmacol Sci. 2011;15(4).
Gupta SK, Malik A, Arukha AP. Ovarian and oocyte targets for development of female contraceptives. Expert Opin Ther Targets. 2015;19(11):1433-46.
Zheng X, Lin D, Zhang Y, Lin Y, Song J, Li S, et al. Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET. Medicine (Baltimore). 2017;96(49):e8842.
Greff D, Juhász AE, Vancsa S, Varadi A, Sipos Z, Szinte J, et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2023;21(1):10.
Agrawal A, Mahey R, Kachhawa G, Khadgawat R, Vanamail P, Kriplani A. Comparison of metformin plus myoinositol versus metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial. Gynecol Endocrinol. 2019;35(6):511-4.
Pacchiarotti A, Carlomagno G, Antonini G, Pacchiarotti A. Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome. Gynecol Endocrinol. 2016;32(1):69-73.
Unfer V, Facchinetti F, Orrù B, Giordani B, Nestler J. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect. 2017;6(8):647-58.
Zhao H, Xing C, Zhang J, He B. Comparative efficacy of oral insulin sensitizers metformin, thiazolidine-diones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. Reprod Health. 2021;18(1):171.
Downloads
Published
How to Cite
Issue
Section
